Does Tirzepatide Lose Potency Over Time? Reading Stability Evidence

First decide what “potency” means in the question

In everyday searches, “losing potency” may mean a lower measured amount of intact material, a change in biological activity or a feeling that treatment has become less noticeable. Those are different observations. Before comparing results, identify which one is actually being measured.

A laboratory report should name the assay and acceptance criterion. A chromatographic result, an activity assay and a visual inspection should not all be compressed into the word “strength.” A clear sample may still need analytical testing, and a result for one attribute does not answer every stability question.

What a labeled expiry date supports

FDA explains that expiration dating and storage conditions are established using stability testing. The date belongs to a product held under the specified conditions; it is not a measurement of what happened to an individual container after an undocumented excursion.

It is also not a day-by-day degradation chart. For example, a 21-day storage allowance does not imply a loss of one twenty-first of the starting potency each day. That calculation would require actual data and a justified model, rather than the date alone.

One molecule, different presentation-specific instructions

Lilly’s U.S. Zepbound prescribing information, revised August 2026 and checked on 4 October, illustrates the distinction. It gives single-dose pens and vials a total unrefrigerated limit of 21 days at no more than 30°C. Its multi-dose vial and KwikPen instructions use different limits, including time at room temperature and time after first use.

The important lesson is to read the section for the exact presentation. An instruction copied from a single-dose pen should not become a general rule for everything labeled tirzepatide. Consult the complete current product instructions for a prescribed medicine; this example is not a replacement for them.

These are instructions for named pharmaceutical presentations. They do not assign a 21-day or 30-day life to a laboratory powder, another supplier’s liquid or a newly prepared research solution.

Three records that should not be merged

When reviewing a storage claim, keep these records separate. Each establishes a different part of the history.

What stability evidence for a research vial should identify

ICH Q1A(R2) describes studying the finished dosage form in its proposed container-closure system and assessing relevant quality attributes over time. It is pharmaceutical-development guidance, but it highlights a useful reading principle: the tested presentation and conditions are part of the result.

For a laboratory material, look for its identity and form, container, conditions, observation times, test methods and acceptance criteria. A report that merely says “stable” does not tell you which attributes remained within which limits. Nor does a result for an unopened dry sample characterize a different liquid preparation.

FDA’s Q7 guidance similarly discusses stability-indicating methods and evidence supporting assigned retest or expiration dates, including when material is repackaged. These sources do not automatically validate a retail research listing; they explain what a defensible stability claim needs to connect.

A practical example: an incomplete temperature history

Imagine a hypothetical research shipment with a delivery timestamp but no record of its temperature before arrival. The package feels cool when opened. That observation describes the arrival condition; it does not reconstruct the earlier journey or quantify any potency change.

A useful next step is to record what is known and ask the supplier for evidence relevant to the specific lot, packaging and suspected excursion. If the information is missing, document the uncertainty and follow the laboratory’s disposition procedure. Do not invent a percentage loss or extend a shelf life from appearance.

If this concerns a prescribed medicine, ask the dispensing pharmacist or manufacturer about that exact product and exposure. Do not compensate for suspected degradation by changing the dose yourself.

A change in perceived response is a different question

Feeling less of an effect is not a chemical assay of the remaining product. It cannot by itself distinguish a storage problem from other explanations. A clinical response concern belongs with the prescriber; a laboratory stability concern needs suitable analytical evidence.

For research procurement, the tirzepatide listing below provides a route to material specifications and available documentation. Its presence here does not make it interchangeable with Zepbound or transfer that medicine’s storage instructions to it.